Published in Mol Interv on April 01, 2011
Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis (2012) 1.60
Microcephaly disease gene Wdr62 regulates mitotic progression of embryonic neural stem cells and brain size. Nat Commun (2014) 1.11
CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res (2013) 1.03
The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest. Nat Commun (2015) 0.97
A conserved role for COMA/CENP-H/I/N kinetochore proteins in the spindle checkpoint. Genes Dev (2012) 0.96
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle (2013) 0.90
Programmed cell death protein 5 interacts with the cytosolic chaperonin containing tailless complex polypeptide 1 (CCT) to regulate β-tubulin folding. J Biol Chem (2013) 0.90
Molecular crosstalk between apoptosis and autophagy induced by a novel 2-methoxyestradiol analogue in cervical adenocarcinoma cells. Cancer Cell Int (2013) 0.89
Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases. PLoS One (2012) 0.89
Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog, in breast cancer cells. PLoS One (2013) 0.89
Mitosis as an anti-cancer drug target. Chromosoma (2013) 0.88
Sulphamoylated 2-methoxyestradiol analogues induce apoptosis in adenocarcinoma cell lines. PLoS One (2013) 0.87
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One (2012) 0.86
Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents. J Med Chem (2013) 0.85
In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Inform (2013) 0.84
USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase. Cell Death Differ (2013) 0.84
Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death. Cell Death Dis (2014) 0.82
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget (2015) 0.82
Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel. PLoS One (2014) 0.81
Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents. J Med Chem (2012) 0.81
BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy. Haematologica (2013) 0.80
Dyskerin localizes to the mitotic apparatus and is required for orderly mitosis in human cells. PLoS One (2013) 0.78
Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. Ann Oncol (2017) 0.78
Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation. Eur J Med Chem (2014) 0.77
Synthesis and biological evaluation of 2-substituted-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorg Med Chem (2012) 0.77
G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound. PLoS One (2015) 0.76
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy. Future Med Chem (2016) 0.75
Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage. Mol Cell Oncol (2017) 0.75
Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin. J Med Chem (2015) 0.75
Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases. Cell Death Dis (2014) 0.75
Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity. J Med Chem (2015) 0.75
Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents. Bioorg Med Chem (2013) 0.75
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
The biochemistry of apoptosis. Nature (2000) 18.91
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
Feedback control of mitosis in budding yeast. Cell (1991) 12.39
S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell (1991) 11.56
The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol (2006) 10.76
Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell (2003) 9.90
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Molecular architecture of the kinetochore-microtubule interface. Nat Rev Mol Cell Biol (2008) 8.21
The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol (2006) 6.85
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med (1997) 6.41
Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol (1999) 5.62
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell (2004) 4.90
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Molecular mechanisms of drug resistance. J Pathol (2005) 4.60
The life and miracles of kinetochores. EMBO J (2009) 4.59
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 4.58
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol (2008) 4.08
Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol (2006) 3.99
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell (2000) 3.88
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell (2005) 3.69
CCAN makes multiple contacts with centromeric DNA to provide distinct pathways to the outer kinetochore. Cell (2008) 3.68
Protein architecture of the human kinetochore microtubule attachment site. Cell (2009) 3.68
The spindle checkpoint, aneuploidy, and cancer. Oncogene (2004) 3.61
Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov (2003) 3.11
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
The spindle assembly and spindle position checkpoints. Annu Rev Genet (2003) 2.84
From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life (2005) 2.79
Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol (2003) 2.64
Kinetochore structure and function. Trends Cell Biol (2005) 2.50
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta (2007) 2.45
How do anti-mitotic drugs kill cancer cells? J Cell Sci (2009) 2.38
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood (1998) 2.31
MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia (2002) 2.17
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta (2007) 2.07
Mcl-1. Int J Biochem Cell Biol (2005) 1.96
c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta (2009) 1.82
Human CENP-I specifies localization of CENP-F, MAD1 and MAD2 to kinetochores and is essential for mitosis. Nat Cell Biol (2003) 1.82
Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem (2002) 1.79
Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets (2003) 1.75
Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest (2005) 1.73
Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci (2009) 1.70
Removal of Spindly from microtubule-attached kinetochores controls spindle checkpoint silencing in human cells. Genes Dev (2010) 1.66
Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol (2005) 1.59
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther (2008) 1.53
Inhibition of p38: has the fat lady sung? Arthritis Rheum (2009) 1.46
Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors (2010) 1.46
Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res (2003) 1.40
Protein kinase CK2--a key suppressor of apoptosis. Adv Enzyme Regul (2008) 1.39
Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem (1998) 1.33
The awesome power of multiple model systems: interpreting the complex nature of spindle checkpoint signaling. Trends Cell Biol (2002) 1.32
Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol (2001) 1.31
Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. Curr Med Chem (2002) 1.29
Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents (2002) 1.28
Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol (2003) 1.12
Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia (1997) 1.02
USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly. EMBO J (2010) 1.01
Bortezomib. Recent Results Cancer Res (2010) 0.99
Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer (2005) 0.96
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2007) 0.95
High-throughput screening for inhibitors of the e3 ubiquitin ligase APC. Methods Enzymol (2005) 0.92
The kinetochore and spindle checkpoint in mammals. Front Biosci (2008) 0.91
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs. Ital J Biochem (2003) 0.88
Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res (2002) 0.86
Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma (2002) 0.86
Inhibition of paclitaxel-induced proteasome activation influences paclitaxel cytotoxicity in breast cancer cells in a sequence-dependent manner. Cell Cycle (2007) 0.84
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep (2008) 0.81
Aurora B kinase cooperates with CENP-E to promote timely anaphase onset. Chromosoma (2010) 0.78
Cell death when the SAC is out of commission. Cell Cycle (2010) 0.78
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol (2002) 8.37
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol (2004) 4.20
Midzone activation of aurora B in anaphase produces an intracellular phosphorylation gradient. Nature (2008) 3.77
Protein architecture of the human kinetochore microtubule attachment site. Cell (2009) 3.68
The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Mol Cell (2002) 3.65
Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol (2006) 3.22
Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol (2002) 3.17
Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell (2005) 3.14
Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science (2010) 3.13
The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity. Genes Dev (2003) 3.04
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
Kinetochore attachments require an interaction between unstructured tails on microtubules and Ndc80(Hec1). Curr Biol (2008) 2.38
The vertebrate Ndc80 complex contains Spc24 and Spc25 homologs, which are required to establish and maintain kinetochore-microtubule attachment. Curr Biol (2004) 2.31
Phosphorylation regulates SIRT1 function. PLoS One (2008) 2.30
Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science (2008) 2.28
The reversibility of mitotic exit in vertebrate cells. Nature (2006) 2.16
Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97
Aurora B kinase and protein phosphatase 1 have opposing roles in modulating kinetochore assembly. J Cell Biol (2008) 1.91
Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol (2005) 1.88
INCENP and Aurora B promote meiotic sister chromatid cohesion through localization of the Shugoshin MEI-S332 in Drosophila. Dev Cell (2006) 1.71
Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function. Mol Biol Cell (2007) 1.66
Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. Sci Signal (2011) 1.62
Measuring the stoichiometry and physical interactions between components elucidates the architecture of the vertebrate kinetochore. Mol Biol Cell (2005) 1.52
Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci U S A (2004) 1.51
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol (2008) 1.46
Multiple mechanisms of chromosome movement in vertebrate cells mediated through the Ndc80 complex and dynein/dynactin. Chromosoma (2007) 1.32
Two complexes of spindle checkpoint proteins containing Cdc20 and Mad2 assemble during mitosis independently of the kinetochore in Saccharomyces cerevisiae. Eukaryot Cell (2005) 1.24
Linking kinetochore-microtubule binding to the spindle checkpoint. Dev Cell (2008) 1.21
Timing of events in mitosis. Curr Biol (2002) 1.20
Xenopus Cep57 is a novel kinetochore component involved in microtubule attachment. Cell (2007) 1.17
Multimodal microtubule binding by the Ndc80 kinetochore complex. Nat Struct Mol Biol (2012) 1.15
The Ndc80 complex: integrating the kinetochore's many movements. Chromosome Res (2011) 1.11
ICIS and Aurora B coregulate the microtubule depolymerase Kif2a. Curr Biol (2009) 1.08
The N-terminal coiled-coil of Ndel1 is a regulated scaffold that recruits LIS1 to dynein. J Cell Biol (2011) 1.07
Cep57, a multidomain protein with unique microtubule and centrosomal localization domains. Biochem J (2008) 1.06
The Ndc80 complex uses a tripartite attachment point to couple microtubule depolymerization to chromosome movement. Mol Biol Cell (2011) 1.05
Phosphatase inhibitor-2 balances protein phosphatase 1 and aurora B kinase for chromosome segregation and cytokinesis in human retinal epithelial cells. Mol Biol Cell (2008) 1.02
A conserved role for COMA/CENP-H/I/N kinetochore proteins in the spindle checkpoint. Genes Dev (2012) 0.96
Perturbation of Incenp function impedes anaphase chromatid movements and chromosomal passenger protein flux at centromeres. Chromosoma (2008) 0.94
Aurora-A kinase and inhibitor-2 regulate the cyclin threshold for mitotic entry in Xenopus early embryonic cell cycles. Cell Cycle (2006) 0.92
Molecular basis for phosphospecific recognition of histone H3 tails by Survivin paralogues at inner centromeres. Mol Biol Cell (2012) 0.91
Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Biochemistry (2012) 0.90
The kinetochore NUPtials. Nat Cell Biol (2003) 0.90
A Hec of a microtubule attachment. Nat Struct Mol Biol (2007) 0.89
EB1 enables spindle microtubules to regulate centromeric recruitment of Aurora B. J Cell Biol (2014) 0.89
Binding of phosphatase inhibitor-2 to prolyl isomerase Pin1 modifies specificity for mitotic phosphoproteins. Biochemistry (2007) 0.89
Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers. Eur J Immunol (2011) 0.88
The distinct functions of CENP-C and CENP-T/W in centromere propagation and function in Xenopus egg extracts. Nucleus (2015) 0.81
Structural features and chaperone activity of the NudC protein family. J Mol Biol (2011) 0.81
Purification of the Ndc80 kinetochore subcomplex from Xenopus eggs. Methods Mol Biol (2005) 0.78
Cdt1 throws kinetochore-microtubule attachments for a loop. Nat Cell Biol (2012) 0.77
Probing kinetochore structure and function using Xenopus laevis frog egg extracts. Methods Mol Biol (2009) 0.76
The quest for the holy "G" of chromosomal passengers. Dev Cell (2003) 0.75
A new histone at the centromere? Cell (2012) 0.75
Cell division: righting the check. Curr Biol (2009) 0.75
Xenopus egg extracts as a simplified model system for structure-function studies of dynein regulators. Methods Mol Biol (2014) 0.75